• Välkommen till PULS monter den 17 september på PARK ANNUAL, Sahlgrenska Science Park, Göteborg
  • PULS deltar på Nordic Life Science Days, den 9 -10 september i Stockholm

A unique Swedish life science development company

PULS turns life science projects into attractive business opportunities for the life science industry. Each project is based on a well-defined medical need. PULS secures long-term financing and world-class scientific and industrial expertise through joint ownership with innovators. Our track record validates all aspects of our business model – a model that serves both innovators and investors well. Try us!

News from PULS

24 August, 2015

LIDDS: Liproca®Depot visar positiva resultat i den förlängda Fas IIa studien

I den förlängda Fas IIa studien, LPC 003, bekräftas att det är möjligt att väsentligt öka injicerad mängd och dos av Liproca® Depot vid prostatacancer. Fem patienter behandlades med mellan 50-200 procent större mängd, i förhållande till prostatans storlek, jämfört med de doser patienterna fick i första delen av studien. Som förväntat sågs sänkta PSA […]

7 July, 2015

Glactone Pharma innovators publish new study showing that the STAT3 inhibitor galiellalactone reduces tumor growth and metastatic spread in an animal model of prostate cancer

Members of Glactone Pharma’s innovator group have published an article in the highly rated scientific journal European Urology: “The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” is published in the journal European Urology, impact factor 13.938 (Eur Urol. 2015, doi:10.1016/j.eururo.2015.06.016).

Find out more
Innovators
Do you have an idea?
Partners
Do you have the knowledge?
Investors
Do you have the experience?

© 2012-2015 P.U.L.S. AB | Kullagatan 8, 252 20 Helsingborg, Sweden | All rights reserved.